Oppenheimer & Close Has Cut Its Position in Eagle Bancorp Mont (EBMT) as Market Value Declined; Johnson & Johnson (JNJ) Holder Tukman Grossman Capital Management Cut Holding by $8.96 Million

December 7, 2017 - By Michael Collier

Tukman Grossman Capital Management Inc decreased its stake in Johnson & Johnson (JNJ) by 29.53% based on its latest 2017Q2 regulatory filing with the SEC. Tukman Grossman Capital Management Inc sold 67,900 shares as the company’s stock rose 6.85% with the market. The institutional investor held 162,038 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $21.44M, down from 229,938 at the end of the previous reported quarter. Tukman Grossman Capital Management Inc who had been investing in Johnson & Johnson for a number of months, seems to be less bullish one the $378.96 billion market cap company. The stock increased 1.00% or $1.39 during the last trading session, reaching $141.06. About 5.59 million shares traded or 4.28% up from the average. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since December 7, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.




Oppenheimer & Close Llc decreased its stake in Eagle Bancorp Mont Inc (EBMT) by 25.26% based on its latest 2017Q2 regulatory filing with the SEC. Oppenheimer & Close Llc sold 28,350 shares as the company’s stock declined 5.97% while stock markets rallied. The institutional investor held 83,900 shares of the finance company at the end of 2017Q2, valued at $1.52M, down from 112,250 at the end of the previous reported quarter. Oppenheimer & Close Llc who had been investing in Eagle Bancorp Mont Inc for a number of months, seems to be less bullish one the $101.50 million market cap company. The stock decreased 1.67% or $0.35 during the last trading session, reaching $20.65. About 6,410 shares traded. Eagle Bancorp Montana, Inc. (NASDAQ:EBMT) has risen 42.05% since December 7, 2016 and is uptrending. It has outperformed by 25.35% the S&P500.

More notable recent Eagle Bancorp Montana, Inc. (NASDAQ:EBMT) news were published by: Globenewswire.com which released: “Larry Williams Joins Eagle Bancorp Montana as Senior Vice President/Chief …” on November 17, 2014, also Marketwatch.com with their article: “Eagle Bancorp Montana Inc.” published on April 16, 2011, Globenewswire.com published: “Eagle Bancorp Montana Announces Private Placement of Senior Unsecured Notes …” on February 13, 2017. More interesting news about Eagle Bancorp Montana, Inc. (NASDAQ:EBMT) were released by: Globenewswire.com and their article: “Eagle Bancorp Montana Announces Promotions, Dale Field promoted to SVP/Chief …” published on July 01, 2014 as well as Globenewswire.com‘s news article titled: “Eagle Bancorp Montana Earns a Record $1.8 Million, or $0.46 per Diluted Share …” with publication date: October 25, 2016.

Analysts await Eagle Bancorp Montana, Inc. (NASDAQ:EBMT) to report earnings on January, 25. They expect $0.34 EPS, down 8.11% or $0.03 from last year’s $0.37 per share. EBMT’s profit will be $1.67 million for 15.18 P/E if the $0.34 EPS becomes a reality. After $0.50 actual EPS reported by Eagle Bancorp Montana, Inc. for the previous quarter, Wall Street now forecasts -32.00% negative EPS growth.

Investors sentiment increased to 3.4 in Q2 2017. Its up 1.57, from 1.83 in 2017Q1. It is positive, as 2 investors sold EBMT shares while 3 reduced holdings. 9 funds opened positions while 8 raised stakes. 2.32 million shares or 115.23% more from 1.08 million shares in 2017Q1 were reported. Missouri-based Kennedy Capital Mngmt has invested 0.01% in Eagle Bancorp Montana, Inc. (NASDAQ:EBMT). 30,236 were accumulated by First Manhattan. Minerva Lc has invested 0.26% in Eagle Bancorp Montana, Inc. (NASDAQ:EBMT). Us National Bank De invested in 13,841 shares. New York-based Renaissance Limited Liability Corp has invested 0% in Eagle Bancorp Montana, Inc. (NASDAQ:EBMT). Deutsche National Bank Ag reported 6,705 shares stake. Tower Research Lc (Trc) invested in 0% or 29 shares. Glacier Peak Cap Ltd Liability Corporation invested in 376,646 shares. Morgan Stanley reported 3,100 shares. Wells Fargo & Mn reported 295 shares or 0% of all its holdings. Panagora Asset Management reported 0% stake. Arrowmark Colorado Holding Ltd Liability accumulated 13,730 shares. Morgan Dempsey Cap Ltd has invested 0.21% of its portfolio in Eagle Bancorp Montana, Inc. (NASDAQ:EBMT). Sei Company reported 1,700 shares. Bridgeway Cap Incorporated invested 0% of its portfolio in Eagle Bancorp Montana, Inc. (NASDAQ:EBMT).

Investors sentiment decreased to 0.83 in 2017 Q2. Its down 0.03, from 0.86 in 2017Q1. It dropped, as 50 investors sold JNJ shares while 878 reduced holdings. 105 funds opened positions while 667 raised stakes. 1.73 billion shares or 0.03% less from 1.73 billion shares in 2017Q1 were reported. Advantus Management holds 0.95% or 271,864 shares. Checchi Cap Advisers Limited Liability Company reported 0.39% stake. Sandler Cap holds 5,310 shares or 0.08% of its portfolio. Pennsylvania Tru Company has invested 2.76% in Johnson & Johnson (NYSE:JNJ). Brandywine Global Investment Mgmt Limited Liability Company accumulated 2.44M shares. Ballentine Prtnrs Ltd Liability Company stated it has 33,450 shares or 0.32% of all its holdings. Bancorporation holds 1.02% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 18,299 shares. Garrison Financial Corporation holds 2.36% or 30,785 shares in its portfolio. Barr E S & has invested 3.97% of its portfolio in Johnson & Johnson (NYSE:JNJ). Diversified Invest Strategies Lc holds 1,670 shares. First Western Cap Mgmt Com owns 5,137 shares or 0.41% of their US portfolio. Burns J W And Inc has 58,456 shares. State Street owns 157.51 million shares or 1.84% of their US portfolio. Reilly Financial Advisors Limited Liability Corporation owns 96,623 shares. Frontier Invest Management accumulated 208,854 shares or 2.7% of the stock.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Fool.com which released: “Better Buy: Pfizer Inc. vs. Johnson & Johnson” on December 01, 2017, also Fiercebiotech.com with their article: “Johnson & Johnson’s JLABS looks east as it lands in Shanghai” published on December 05, 2017, Forbes.com published: “The Outlook For Johnson & Johnson’s Immunology Drug Business” on December 05, 2017. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Johnson & Johnson: Buy The Pause” published on November 29, 2017 as well as Seekingalpha.com‘s news article titled: “The Right Time To Buy Johnson & Johnson” with publication date: November 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: